Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).Wen Wee, Eliel Bayever, Cesar A. Perez et al.|Journal of Clinical Oncology|2023Cited by 7